149709-62-6

Hazard Information

Questions And Answer

• Pharmacologic action

  AHU377 and angiotensin IIAT1 receptor antagonist valsartan at a molar ratio of 1: 1 compose LCZ696. LCZ696 was a dual inhibitor of angiotensin II (AT2) receptor and enkephalinase (Neprilysin) receptor. And with its better antihypertensive efficacy than standard antihypertensive drugs, it is a new drug for the treatment of heart failure.
  AHU377 is a prodrug that converts the active form of the enzyme cleavage LBQ657 ethyl ester. So far its efficacy and safety in milestone phase III surpass the clinical standard drug enalapril.
  In a clinical trial of the drug, 100 to 400 mg of combined drugs, 80 to 320 mg of valsartan, 200 mg of neprilysin inhibition or placebo were given to the patients in the double-blind trial of phase two with mild to moderate hypertension. The combined drugs are more effective and better tolerated with no vascular edema report than solely applied valsartan or other drugs. LCZ696 shows sustainable treatment benefits in the early treatment:
  (1) a 20% reduction in the risk of death from cardiovascular disease (p = 0.00004).
  (2) hospitalization for heart failure was reduced by 21% (p = 0.00004).
  (3) all-cause mortality was reduced by 16% (p = 0.0005).
  (4) The overall risk is reduced by 20% according to the composite measure of the primary endpoint of hospitalization for cardiovascular death or heart failure (p = 0.0000002).;

• Novartis’ New Angiomyocardiac LCZ696

  According to a recent study published by Novartis, LCZ696, a cardiovascular drug being developed by the company, will become a new hope for the company. The current study shows that this drug functions well in the remission of cardiovascular necrosis and other symptoms caused by heart disease.
  LCZ696 is a combination of Novartis Diovan and AHU-377. Some analysts have spoken highly of the drug and estimated that it might be submitted to the FDA as early as next year. Once confirmed in the audit it will mark another great step forward of Novartis in the field of cardiovascular drugs.
  Although it showed high expectations to LCZ696, Novartis still has a long way to go, given the setbacks of its serelaxin in the FDA and the European Medicines Administration.
  The news came straight from Basel as investigators around the world were wrapping up the big scientific meeting of the American College of Cardiology.;

• Market analysis

  In the field of research and development of drugs, most of the success of the new drugs in phase II will always lead to a series of competitor projects. The LCZ696 performs so prominently that the industry was shocked. It is predicted that few cardiovascular drugs will be qualified to compete with the LCZ696 in the next few years. Some analysts predict that the LCZ696 sales will peak at $ 8 billion, while Deutsche Bank analysts expect the drug to peak at $ 6 billion, given LCZ696's superior performance in reducing cardiovascular risk. Although the data are slightly different, there is no doubt that, LCZ696 will become a super star to lead the cardiovascular treatment to step into a new era.;

Spectrum Detail

Supplier

Related Products